A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of
Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202
study provided strong evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial
effects upon pain, sleep and other FM symptomatology.
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets,
taken daily at bedtime over 12 weeks to treat fibromyalgia.